Long-term pretreatment with an angiotensin II AT 1 antagonist blocks angiotensin II effects in brain and peripheral organs and abolishes the sympathoadrenal and hypothalamic-pituitary-adrenal responses to isolation stress. We determined whether AT 1 receptors were also important for the stress response of higher regulatory centers. We studied angiotensin II and corticotropin-releasing factor (CRF) receptors and benzodiazepine binding sites in brains of Wistar Hannover rats. Animals were pretreated for 13 days with vehicle or a central and peripheral AT 1 antagonist (candesartan, 0.5 mg/kg/day) via osmotic minipumps followed by 24 h of isolation in metabolic cages, or kept grouped throughout the study (grouped controls). In another study, we determined the influence of a similar treatment with candesartan on performance in an elevated plus-maze. AT 1 receptor blockade prevented the isolation-induced increase in brain AT 1 receptors and decrease in AT 2 binding in the locus coeruleus. AT 1 receptor antagonism also prevented the increase in tyrosine hydroxylase mRNA in the locus coeruleus. Pretreatment with the AT 1 receptor antagonist completely prevented the decrease in cortical CRF 1 receptor and benzodiazepine binding produced by isolation stress. In addition, pretreatment with candesartan increased the time spent in and the number of entries to open arms of the elevated plus-maze, measure of decreased anxiety. Our results implicate a modulation of upstream neurotransmission processes regulating cortical CRF 1 receptors and the GABA A complex as molecular mechanisms responsible for the anti-anxiety effect of centrally acting AT 1 receptor antagonists. We propose that AT 1 receptor antagonists can be considered as compounds with possible therapeutic anti-stress and anti-anxiety properties.
INTRODUCTION
Angiotensin II (Ang II) contributes to regulate the sympathetic and neuroendocrine systems and it is an important stress hormone (Saavedra, 1992; Phillips, 1997) . There are two types of Ang II receptors, the AT 1 and AT 2 types. The well-known physiological actions of Ang II are dependent on AT 1 receptor stimulation; the physiological role of AT 2 receptors is controversial (Saavedra, 1999; De Gasparo et al, 2000) . AT 1 receptors are present throughout the hypothalamic-pituitary-adrenal axis (HPA), highly concentrated in key areas regulating the stress response (Tsutsumi and Saavedra, 1991a, b; Jöhren et al, 1995; Israel et al, 1995) . During stress, there is increased renin production and higher circulating and brain Ang II (Xang et al, 1993; Yang et al, 1996) , leading to enhanced stimulation of peripheral and brain AT 1 receptors. In addition, isolation (Armando et al, 2001 ; present results) and restraint (Castrén and Saavedra, 1988; Leong et al, 2002; Aguilera et al, 1995a) increased AT 1 receptor expression in brain areas inside and outside the bloodbrain barrier and related to the control of the hormonal and sympathoadrenal responses to stress, probably as a result of stimulation of glucocorticoid response elements in the receptor promoter region by increased corticosterone levels (Guo et al, 1995) . This indicates that stress is likely to increase the effects of brain-generated Ang II and those of circulating Ang II in the brain (Saavedra, 1992) .
Stress increases the AT 1 receptor expression in the parvocellular hypothalamic paraventricular nucleus (PVN), the site of corticotropin-releasing factor (CRF) formation (Castrén and Saavedra, 1988; Aguilera et al, 1995a; Jezova et al, 1998; Leong et al, 2002) , and stimulation of AT 1 receptors in the PVN by Ang II increases CRF production (Sumitomo et al, 1991; Aguilera et al, 1995b) . AT 1 receptors from the PVN are transported to the median eminence through axons coexpressing CRF (Oldfield et al, 2001) . Released into the hypothalamic portal system, CRF increases pituitary ACTH. These findings indicate that upregulation of AT 1 receptors in the PVN is a major factor modulating the increased CRF production, which is followed by a cascade of stimulated ACTH release and increased adrenal corticoid secretion, the hallmark of the stress reaction.
Because AT 1 receptor stimulation enhanced CRF formation and release during stress, it was reasonable to ask whether a limitation of the Ang II tone maintained over time, such as that resulting from long-term antagonism of AT 1 receptors, could decrease or prevent the hormonal response to stress. We demonstrated that long-term treatment with candesartan, an insurmountable AT 1 antagonist that, when administered peripherally, readily inhibits not only peripheral but also central AT 1 receptors (Nishimura et al, 2000) , abolished the HPA axis and sympathoadrenal response to isolation in rats (Armando et al, 2001) . Isolation is a clinically relevant model of emotional stress resulting from the restriction from freely regulating exposure to novel surroundings and access to familiar territory. In addition, candesartan pretreatment prevented the gastric ulceration produced by cold-restraint stress in rats . This suggested that antagonism of peripheral and brain AT 1 receptors could be of therapeutic relevance in the control of the stress reaction (Armando et al, 2001) .
In addition to the hypothalamus, brain AT 1 receptors are expressed in many other areas including the cortex, indicating the possibility of a role of Ang II in behavior (Tsutsumi and Saavedra, 1991a; Lenkei et al, 1998) . Overexpression of AT 1 receptors in mice lacking AT 2 receptors associates with anxietylike behavior (Okuyama et al, 1999) . Of particular interest was the finding that peripheral administration of the AT 1 receptor antagonist losartan reduces anxiety in rodents (Barnes et al, 1990) . These findings suggest that AT 1 receptor stimulation enhances anxiety and that these receptors regulate not only the autonomic and hormonal but also the behavioral response to stress.
We asked the question whether AT 1 receptor antagonists could modulate the response of cortical and subcortical structures to stress. We focused on systems that play recognized roles in stress and anxiety, the cortical, amygdaloid, and septal CRF receptors, cortical benzodiazepine binding sites (part of the inhibitory GABA A complex) (Nutt and Malizia, 2001; Zavala, 1997; Biggio et al, 1990) , and tyrosine hydroxylase (TH) in the locus coeruleus, the site of origin of noradrenergic neurons innervating the cortex (Koob, 1999; Dunn and Berridge, 1990; Whitnall, 1993) . We tested the effects of long-term pretreatment with an AT 1 antagonist on cortical and subcortical CRF and cortical benzodiazepine receptor binding and TH mRNA in the locus coeruleus in animals subjected to isolation stress, and studied the effect of a similar treatment on the behavior of the animals in the elevated plus-maze, a conflict test reflecting anxiety (Lister, 1987) .
MATERIALS AND METHODS

Animals and Preparation of Tissues
Wistar Hannover male rats (8 weeks old) were purchased from Taconic Farms, Germantown, NY, kept at 221C under a 12 : 12-h dark-light cycle with lights on at 0700 hours and were given free access to normal rat diet and tap water. The NIMH Animal Care and Use Committee approved all procedures. All efforts were made to minimize the number of animals used and their suffering (NIH Guide for the Care and Use of Laboratory Animals, NIH Publication No. 80-23, revised 1996) .
We used different groups of six rats each to determine (a) Ang II receptor type binding and TH mRNA, (b) CRF receptor and benzodiazepine binding, and (c) behavior in the elevated plus-maze.
Experiment 1. Determination of Ang II Receptor Binding and TH mRNA
Rats were anesthetized with pentobarbital (30 mg/kg), and Alzet osmotic minipumps (Alza Scientific Products, Palo Alto, CA) were implanted subcutaneously. Groups of animals received minipumps containing vehicle or candesartan (ASTRA, Mölndal, Sweden) dissolved in 1 mol/l sodium carbonate and further diluted in isotonic saline, at a final pH of 7.5-8.0, to be delivered at a rate of 0.5 mg/kg/day. The dose of 0.5 mg/kg/day was selected because it produced a very significant decrease in binding to brain AT 1 receptors (Nishimura et al, 2000) and was effective in blocking the sympathoadrenal and hormonal response to isolation stress (Armando et al, 2001) . After minipump implantation, the rats were kept in their cages in groups of 3-4 for 13 days.
For the isolation experiments, at the end of day 13 of treatment, animals treated with candesartan or vehicle were individually housed in standard, 50 square inch plastic metabolic cages (Nalgene, Rochester, NY) that were located in the same animal room. Control animals (referred as grouped rats) treated with candesartan 0.5 mg/kg/day or vehicle remained grouped 3-4 animals per cage and undisturbed in the same animal room as the isolated rats. Regular rat food and water were provided ad libitum throughout the experiment. At the end of the experiment, on day 14, all animals were killed by decapitation and the brains were removed, frozen in isopentane at À301C on dry ice, and stored at À801C until used. These animals were used to determine Ang II receptor binding and TH mRNA as described below.
Experiment 2. Autoradiographic Determination of CRF Receptor and Benzodiazepine Binding
Additional groups of 8-week-old Wistar Hannover rats were housed, treated as above with vehicle or candesartan for 13 days, submitted to isolation stress, killed at the end of day 14, and the brains were removed and processed as described above. These animals were used to determine CRF and benzodiazepine receptor binding as described below.
Experiment 3. Study on the Elevated Plus-Maze
Additional groups of 8-week-old Wistar Hannover rats were housed in groups of three to four rats and treated as above with vehicle or candesartan for 13 days. On day 14, between 0900 and 1100, the animals were tested in the elevated plusmaze as described below.
Ang II Receptor Binding
We cut 16-mm-thick brain coronal sections in a cryostat at À201C, thaw-mounted the sections on poly-1-lysine-coated slides (Labscientific Inc., Livingston, NJ), dried them overnight in a desiccator at 41C, and stored them at À801C until used. Sections were labeled in vitro with 0. -Ang II, Peninsula Laboratories, Belmont, CA; iodinated by the Peptide Radioiodination Service Center, School of Pharmacy, University of Mississippi, to a specific activity of 2176 Ci/ mmol). Sections were preincubated for 15 min at 221C in 10 mM Na phosphate buffer, pH 7.4, containing 120 mM NaCl, 5 mM Na 2 EDTA, 0.005% bacitracin (Sigma Chemical, St Louis, MO), and 0.2% bovine serum albumin proteinase free (Sigma Chemical), followed by incubation for 120 min in fresh buffer containing 0.5 nM of [
125 I]Sar 1 -Ang II. We determined total binding by incubating the sections as described above (Tsutsumi and Saavedra, 1991a) . Nonspecific binding was determined in consecutive sections incubated as above in the presence of 1 mM unlabeled Ang II (Peninsula), and was the binding remaining in the presence of excess unlabeled agonist. Specific binding to all Ang II receptors was the difference between total binding and nonspecific binding, which is the binding displaced by excess labeled agonist. To determine selective binding to the Ang II receptor types (AT 1 and AT 2 receptors), we incubated consecutive sections with 0.5 nM of [ (1 mM; Sigma), selected to give maximum specific displacement. The number of AT 1 and AT 2 receptors was the binding displaced by the AT 1 or AT 2 receptor antagonists, respectively (Tsutsumi and Saavedra, 1991a) .
After incubation, slides were rinsed four consecutive times, for 1 min each, in fresh ice-cold 50 mM Tris-(hydroxymethyl)aminomethane.HCl buffer, pH 7.6, followed by a dip in ice-cold distilled water, and the sections were dried under air (Tsutsumi and Saavedra, 1991a) . Sections were exposed to Kodak Biomax MR film (Eastman Kodak Company, Rochester, NY) together with 14 C-labeled microscales (American Radiolabeled Chemicals, St Louis, MO). Films were developed in ice-cold GBX developer (Eastman Kodak) for 4 min, fixed in Kodak GBX fixer for 4 min at 221C, and rinsed in water for 15 min. Optical densities of autoradiograms generated by incubation with the 125 I-labeled ligands were normalized after comparison with 14 C-labeled standards as described (Miller and Zahniser, 1987) , by computerized densitometry using the Image 1.6 Program (National Institute of Mental Health, Bethesda, MD). The films were exposed for different times, depending on the amount of binding present, to obtain film images within the linear portion of the standard curve and transformed to corresponding values of fmol/mg protein (Nazarali et al, 1989; Miller and Zahniser, 1987) . Because we used single ligand concentrations below saturation, there is no information as to whether the changes described represent alterations in receptor number or receptor affinity. Each animal was quantified independently. Brain regions were identified according to Paxinos and Watson (1986) by staining of consecutive sections with toluidine blue.
In Situ Hybridization of TH mRNA
For in situ hybridization experiments, 16-mm-thick brain sections consecutive to those used for receptor binding were collected as mentioned above and stored at À801C until assayed. We synthesized one antisense oligonucleotide of 48-mer for the rat TH cDNA sequence (Lofstrand Labs Limited, MD), localized in nt 1562-1609 (Grima et al, 1985) , and labeled the oligonucleotide with terminal deoxynucleotidyl transferase (Amersham) to a specific activity of 3-4 Â 10 8 dpm/mg. Each reaction was performed with 70 pmol of oligonucleotides in the presence of 70 mCi of [a-35 S]ATP (Amersham). The labeled oligonucleotides were separated from unincorporated nucleotides using MicroSpin G-25 columns (Amersham). In situ hybridization of rat brain sections and posthybridization washings were performed as described (Wisden and Morris, 1994) in consecutive brain sections, one incubated with labeled antisense oligonucleotide and another with labeled oligonucleotide in the presence of excess unlabeled probe (157 pmol/ml). After exposure to BioMax MR films (Kodak), the films were developed and quantified by comparison with 14 C-labeled standards (American Radiolabeled Chemicals).
Autoradiography of CRF Receptors
We cut 16-mm-thick brain coronal sections in a cryostat at À201C, thaw-mounted the sections on poly-1-lysine-coated slides (Labscientific Inc., Livingston, NJ), dried them overnight in a desiccator at 41C, and stored them at À801C until used. Consecutive brain sections were preincubated twice for 10 min in 50 mM Tris buffer, pH 7.4, followed by incubation for 60 min at room temperature in 50 mM Tris buffer, pH 7.4, containing 10 mM MgCl 2 , 0.1% BSA, 0.05% bacitracin, and 0.2 nM [ 125 I]sauvagine (specific activity 2200 Ci/mmol; Perkin-Elmer, Boston, MA) to label both CRF 1 and CRF 2 receptor subtypes (Rominger et al, 1998 (Rominger et al, 1998; Schulz et al, 1996; Webster et al, 1996; McCarthy et al, 1999) . The [ 125 I]sauvagine binding not displaced by antalarmin but displaced in the presence of 1 mM hCRF was considered as binding to CRF 2 receptors. Following the incubation period, slides were washed twice, 5 min each, in Tris buffer (50 mM) containing 0.01% Triton X-100 at 41C. Slides were washed in deionized water, dried under cold air, exposed to Kodak Biomax MR film (Eastman Kodak Company, Rochester, NY) together with 14 C-labeled standards, and developed and quantified as described above. Cortical areas (cingulate, frontal, and parietal), the lateral septal nucleus, and the amygdaloid complex were defined according to Paxinos and Watson (1986) .
Autoradiography of Benzodiazepine Binding Sites
Brain sections (16-mm-thick) were incubated for 90 min at 41C in assay buffer (50 mM Tris-citrate pH 7.1 containing 150 mM NaCl) and 1 nM of the nonselective benzodiazepine agonist [ H]flunitrazepam displaced in the presence of 1 mM clonazepam in consecutive sections was considered as binding to central benzodiazepine receptors (BZ1 and BZ2) (Negro et al, 1995; Fernández-López et al, 1997) . After incubation, sections were washed five times for 5 min in incubation buffer at 41C and dipped once in ice-cold distilled water. Slides were dried and exposed to Kodak Biomax MR film for 1 week together with 3 H-labeled standards. Films were developed as above, and images quantified as described above with comparison to 3 H-labeled standards (Orchinik et al, 2001) . Cortical areas were defined as above (Paxinos and Watson, 1986) .
Elevated Plus-Maze
The plus-maze apparatus was made of stainless steel and consisted of four arms elevated 50 cm above the ground, with each arm (50 cm long and 10 cm wide) positioned 901 relative to the adjacent. The arms extended from a central platform with two closed arms (walls 40 cm high) and two open arms (Columbus Instruments, Columbus, OH). Testing was conducted in a quiet room. To facilitate adaptation, the animals were placed in the behavioral room 1 h before testing.
Rats were placed in the center of the plus-maze facing an open arm (Rodgers and Johnson, 1998) , and we recorded the percent of time spent in the open arms and the number of entries in the open and closed arms. Arm entry was defined as placing all four paws on it, and the duration of the test was 5 min for each animal (Montgomery, 1955) .
Statistics
Data are means7SEM, for groups of six animals measured individually. Two-way ANOVA followed by the NewmanKeuls test was used to assess the significance of differences in receptor binding, TH mRNA, and CRF content among groups. Unpaired Student's t-test was used to assess the significance of differences in the behavior display in the plus-maze. po0.05 was considered as statistically significant.
RESULTS
Effect of Isolation and AT 1 Antagonism on Expression of Ang II Receptors and TH mRNA in the Brain
In grouped animals, subcutaneous administration of the AT 1 antagonist for 14 days substantially decreased the binding to AT 1 receptors in all areas studied. The binding to AT 2 receptors was not affected by the treatment (Table 1) . The significant reduction in binding to AT 1 receptors in grouped, nonstressed animals very likely represents insurmountable binding of candesartan (Nishimura et al, 2000; Armando et al, 2001) .
In vehicle-treated animals, isolation increased significantly AT 1 binding in the PVN, subfornical organ, nucleus of the solitary tract, and area postrema (Table 1) . Conversely, isolation significantly decreased the binding to AT 2 receptors in the locus coeruleus and inferior olive (Table 1 and Figure 1) . Pretreatment of the animals with the AT 1 antagonist abolished the increase in AT 1 receptors in all areas studied and reversed the decrease in AT 2 binding in the locus coeruleus and the inferior olive (Table 1 and Figure 1) .
Administration of the AT 1 antagonist to grouped animals had no effect on the expression of TH mRNA in the locus coeruleus. Isolation significantly increased TH mRNA in vehicle-treated animals, and pretreatment with the AT 1 antagonist completely prevented the isolation-induced increase in TH mRNA (Figure 1 expressing about two-fold higher binding than cortical layers I-III and V-VI (Figures 2-4) .
The number of cortical CRF 2 receptors (binding not displaced by antalarmin but displaced by unlabeled CRF) represented about 25-40% of the total binding to CRF receptors (Table 2 and Figure 2 ). Higher numbers of CRF 2 receptors were expressed in layer IV of the parietal cortex (Table 2 ). (Figures 3 and 4) . In all cortical layers, pretreatment with the AT 1 antagonist completely prevented the decrease in CRF 1 binding, which occurred in animals subjected to isolation stress (Figures 3 and 4) .
Conversely, the expression of CRF 2 receptors was not significantly altered by isolation or pretreatment with the AT 1 receptor antagonist, in any of the cortical areas studied ( Table 2) .
Effect of Isolation and AT 1 Receptor Antagonism on Expression of CRF Receptors in Septum and Amygdala
In the lateral septum, only CRF 2 , but not CRF 1 , receptors were expressed. There was no significant change in CRF 2 receptors when grouped animals were treated with candesartan, and no significant changes in CRF 2 receptor expression were detected after isolation. Pretreatment of isolated animals with candesartan produced a small (15%) but statistically significant increase in CRF 2 receptor expression. Values were 2.3870.20, 2.0870.25, 2.1970.15, and 2.5370.12 fmol/mg protein for grouped, grouped treated with candesartan, isolated, and isolated treated with candesartan, respectively (po0.05, isolated treated with candesartan vs all other groups).
In the amygdala complex, we detected both CRF 1 and CRF 2 receptors. There were no significant changes in expression of either receptor type after treatment of grouped animals with candesartan, after isolation, or after pretreating isolated animals with candesartan. Figure 5 ).
Benzodiazepine binding was unevenly distributed in the cortical areas studied. Highest binding was present in the cingulate cortex and in layer IV, corresponding to the granular layer, of the parietal cortex (Figures 5-7) .
Pretreatment of the animals with the AT 1 receptor antagonist did not modify the binding to central benzodiazepine receptors in grouped animals (Figures 6 and 7) . In animals subjected to isolation stress, benzodiazepine binding was significantly decreased in all cortical areas studied (Figures 6 and 7) , and this decrease was completely prevented by pretreatment of the animals with the AT 1 receptor antagonist (Figures 6 and 7) .
Effect of Pretreatment with an AT 1 Receptor Antagonist on the Behavior in the Elevated Plus-Maze
Administration of the AT 1 antagonist to grouped animals for 13 days before the testing increased the number of entries into open arms and increased the percent of the time spent in the open arms. Entries into closed arms were not affected by the treatment (Figure 8 ).
DISCUSSION
The main finding of this study is that pretreatment with a centrally acting Ang II AT 1 receptor antagonist prevents the isolation stress-induced alterations in cortical CRF 1 and benzodiazepine binding and locus coeruleus TH mRNA, and reduces anxiety in the elevated plus-maze. This indicates that AT 1 receptor antagonists exert anti-stress and anti-anxiety properties by modulating three interacting cortical systems, CRF, GABA A , and norepinephrine.
We confirmed that subcutaneous administration of the insurmountable and selective AT 1 receptor antagonist candesartan blocked brain AT 1 receptors, demonstrating that the compound crossed the blood-brain barrier and is an effective agent to antagonize the effects of brain Ang II (Nishimura et al, 2000; Seltzer et al, 2004) . Pretreatment with the AT 1 antagonist, by preventing the hormonal response to isolation, prevented the glucocorticoid-induced increase in receptor transcription (Armando et al, 2001; Leong et al, 2002; present results) and the corresponding increase in expression of AT 1 receptors in the PVN (Armando et al, 2001 ).
The locus coeruleus, the site of origin of the sympathetic innervation to the cortex, participates in the well-characterized stress-induced central sympathetic stimulation (Carrasco and Van de Kar, 2003; Berridge and Waterhouse, 2003) . AT 1 stimulation enhances central norepinephrine formation and release (Saavedra, 1992) . Pretreatment with AT 1 antagonists prevented the sympathoadrenal response to isolation (Armando et al, 2001 ) and the increase in TH mRNA in the locus coeruleus after central administration of Ang II (Seltzer et al, 2004) . For these reasons, it was not surprising to find that pretreatment with candesartan prevented the stress-induced increase in TH mRNA in the locus coeruleus (present results).
However, in the rat, the locus coeruleus does not express AT 1 receptors, but large numbers of Ang II AT 2 receptors Tsutsumi and Saavedra, 1991a; present results) . Isolation (present results) or cold stress (Peng and Phillips, 2001) decrease AT 2 binding in the locus coeruleus, a change in opposite direction to that of forebrain and brainstem AT 1 receptors during stress. We found that, in parallel with a reversal of the isolation-induced increase in TH mRNA, candesartan prevented the isolation-induced decrease in AT 2 binding in the locus coeruleus. These findings suggest that, whereas brain AT 1 receptors are clearly involved in the control of the central sympathetic drive through regulation of TH transcription, AT 1 receptor antagonists prevent the stressinduced increase in central sympathetic drive by indirect effects requiring AT 2 receptor participation. In support of this hypothesis, we reported a dual role for AT 1 and AT 2 receptors in the control of basal TH transcription and catecholamine formation in the adrenal medulla .
The coordination of behavioral and autonomic responses to stress, including fear and anxiety (Dunn and Berridge, 1990; Whitnall, 1993; Carrasco and Van de Kar, 2003) , is partially under the control of extrahypothalamic, including cortical, CRF neurons predominantly expressing CRF 1 receptors (Bittencourt and Sawchenko, 2000; Chalmers et al, 1995; Van Pett et al, 2000) . CRF 1 receptor activity is important for the induction of anxiety, and CRF 1 (corticotropin-releasing hormone) receptor antagonists decrease stress-induced anxiety (Menzaghi et al, 1994; Rodriguez de Fonseca et al, 1996; Millan et al, 2001; Smith et al, 1998) .
Cortical CRF 1 receptor binding decreases after isolation (present results), foot shock (Anderson et al, 1993) , and chronic unpredictable stress (Iredale et al, 1996) . Central administration of CRF downregulated CRF 1 binding in the frontal cortex (Brunson et al, 2002) and incubation of a neuron-derived cell line with CRF decreased the levels of CRF 1 mRNA (Iredale et al, 1996) . For these reasons, the stress-induced decrease in CRF 1 receptors has been related to ligand-induced downregulation in response to increased peptide release (Carrasco and Van de Kar, 2003) . In support of this hypothesis, we found a decrease in cortical CRF levels of rats submitted to cold restraint, a change prevented by pretreatment with candesartan (unpublished results).
We report that pretreatment with the AT 1 antagonist candesartan prevents the isolation-induced decrease in cortical CRF 1 binding. The stress-induced release of cortical CRF may be positively regulated by cortical AT 1 receptor stimulation, in a manner similar to that occurring at the hypothalamic level. Autoradiographic studies revealed AT 1 receptors in the entorhinal and piriform cortex, but not in the neocortex (Tsutsumi and Saavedra, 1991a) , possibly because of limitations in the power of cellular resolution of the film autoradiography. However, expression on neocortical AT 1 receptor mRNA was detected with in situ hybridization (Lenkei et al, 1998) , indicating the existence of a cortical AT 1 receptor system. Thus, blockade of cortical AT 1 receptors could directly reduce CRF release and prevent CRF 1 receptor downregulation. Alternatively, or in addition, AT 1 receptor antagonism could prevent the stressinduced decrease on cortical CRF 1 receptors by decreasing TH transcription in the locus coeruleus. There is a reciprocal relationship between the brain CRF and sympathetic systems, and CRH contributes to activation of the locus coeruleus during stress (Berridge and Waterhouse, 2003) . Stress increases CRF concentrations in the locus coeruleus (Chappell et al, 1986) , local application of CRF in the locus coeruleus induces behavioral activation (Butler et al, 1990) , and i.c.v. administration of a CRF antagonist blunts the stress-induced increase in extracellular norepinephrine levels in the prefrontal cortex (Shimizu et al, 1994) . This in turn could decrease CRF release from cortical neurons, as it is known that at least in the hypothalamus CRF release is under noradrenergic control (Szafarczyk et al, 1995) .
In addition to CRF 1 receptors, there are cortical CRF 2 receptors in rats (Primus et al, 1997) and nonhuman primates (Sánchez et al, 1999) . The modulatory effect of the AT 1 receptor antagonist appears restricted, in cortical areas, to CRF 1 receptors, as the expression of cortical CRF 2 receptors is not altered by candesartan pretreatment.
The role of brain AT 1 receptors may not be limited to that of regulatory functions in cortical structures, the focus of the present study, but may very well extend to subcortical limbic structures such as the amygdala, septum, and hippocampus, the site of large numbers of AT 1 receptors (Tsutsumi and Saavedra, 1991a) . For this reason, we examined the effects of isolation and candesartan treatment on the expression of CRF receptors in the septum and amygdaloid complex, part of a circuit that plays a major role in the regulation of the stress response (Carrasco and Van de Kar, 2003; Herman et al, 2003) . In the amygdaloid complex, we found no isolation-induced alterations and no changes after candesartan treatment in CRF 1 or CRF 2 receptor expression, indicating that the effects of AT 1 receptor blockade in CRF 1 receptors may be restricted to cortical areas.
In our experiments, we did not detect significant numbers of CRF 1 receptors in the lateral septum, a region with very low expression of CRF 1 receptor mRNA (Chalmers et al, 1995) . In isolated rats treated with candesartan, there was a small increase in septal CRF 2 receptors. This finding may be of interest because activation of CRF 2 receptors reverses anxiety-like behavior (Valdez et al, 2004) and CRF 2 receptors have been proposed as regulators of the stress response (Risbrough et al, 2004) .
In the cortex, CRF negatively modulates the activity of the GABA A complex, the main central inhibitory system (Takamatsu et al, 1991; Serra et al, 1999) . The CRF and GABA A systems are tightly interconnected, and in the PVN, GABA A receptors colocalize with CRF neurons (Cullinan, 2000) . A similar interaction is likely to occur in the cortex. The effect of CRF 1 antagonists is similar to the effect of the benzodiazepines, the classical anxiolytic compounds, which stimulate central benzodiazepine sites, part of the inhibitory GABA A receptor complex (Nutt and Malizia, 2001; Zavala, 1997; Biggio et al, 1990) . Stimulation of central benzodiazepine receptors increases the affinity of GABA for its binding site through positive allosteric effects, potentiating GABAergic transmission (Zavala, 1997) . Isolation (present results) or exposure to inescapable stressors such as foot shock or forced swimming (Lippa et al, 1978; Weizman et al, 1989; Medina et al, 1983) decreased benzodiazepine receptor binding in the frontal cortex. In turn, decreased benzodiazepine binding decreases GABAergic transmission, and this leads to stress-induced anxiety (Nutt and Malizia, 2001) . Our finding of decreased cortical benzodiazepine receptor binding during isolation is most likely associated with the stress-induced increase in cortical CRH release. By decreasing CRF release, AT 1 receptor blockade would also reverse the stress-induced decrease in central benzodiazepine binding and restore the inhibitory influence of the GABA A complex during isolation.
In the elevated plus-maze, a test of anxiety-related behavior (Lister, 1987) , pretreatment with candesartan increased the number of entries into the open arm of the maze and the time spent in the open arm, indicating a clear anxiolytic effect, similar to that found after peripheral administration of other AT 1 receptor antagonists (Barnes et al, 1990; Kaiser et al, 1992) and to that of CRF 1 receptor antagonists (Korte and De Boer, 2003; Millan et al, 2001) .
Our results are not without clinical implications. Hyperactivity of the HPA axis and of CRF neurons regulating higher brain centers are confirmed findings in anxiety and in stress-related affective disorders (Bremner et al, 2000; Keck and Holsboer, 2001) . We demonstrate here that inhibition of Ang II AT 1 receptors is sufficient to block stress-induced changes in CRF 1 receptors and to restore the inhibitory effect of the cortical GABA A system. Our hypothesis is that these effects explain the anxiolytic and anti-stress effects of centrally active AT 1 receptor antagonists.
Our observations indicate that Ang II AT 1 receptors are involved in higher regulatory mechanisms controlling the behavioral and cognitive responses to stress and anxiety. Antagonism of brain Ang II AT 1 receptors could open a new lead in the treatment of anxiety and other stress-related psychiatric conditions such as depression and posttraumatic stress disorder.
